---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-006049"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T14:22:15.429195+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology reports FY2022 cash of $105.3M; provides clinical updates for onvansertib

## Summary
- Cash, cash equivalents, and short-term investments $105.3M at Dec 31, 2022; projected runway into 2025.
- Total operating expenses $40.3M for FY2022, up $11.1M from FY2021; net cash used in operations $33.8M.
- Phase 1b/2 mCRC trial: ORR 35% (n=48), median PFS 9.3 months; bevacizumab-naïve subgroup ORR 69%, mPFS 13.5 months.
- Appointed Fairooz Kabbinavar as CMO, Tod Smeal as CSO, Charles Monahan as SVP Regulatory Affairs.
- Upcoming data readouts: mPDAC and SCLC in Q2/Q3 2023; TNBC in Q4 2023/Q1 2024; ONSEMBLE mCRC randomized data in Q3/Q4 2024.

## SEC filing metadata
- accession: 0001628280-23-006049
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828023006049/0001628280-23-006049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828023006049/crdf-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-006049
- JSON: https://secwatch.observer/filing/0001628280-23-006049.json
- Plain text: https://secwatch.observer/filing/0001628280-23-006049.txt

## Key facts
- Earnings Releases
  Cardiff Oncology, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023006049/0001628280-23-006049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.